Similar articles

• Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?

  Cole JH, Weintraub WS. Cole JH, et al. Circulation. 2003 Dec 9;108(23):2831-3. doi: 10.1161/01.CIR.0000106681.88891.F2. Circulation. 2003. PMID: 14662689 No abstract available.
• Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.

  Boersma E. Boersma E. J Am Coll Cardiol. 2007 Jan 16;49(2):276; author reply 277. doi: 10.1016/j.jacc.2006.10.020. Epub 2006 Dec 29. J Am Coll Cardiol. 2007. PMID: 17222743 No abstract available.
• Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.

  Khan SS, Forrester J. Khan SS, et al. N Engl J Med. 1997 Oct 23;337(17):1243; author reply 1244-5. doi: 10.1056/NEJM199710233371716. N Engl J Med. 1997. PMID: 9340527 No abstract available.
• Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.

  Exaire JE, Lincoff AM. Exaire JE, et al. J Thromb Haemost. 2004 Jan;2(1):7-9. doi: 10.1111/j.1538-7836.2004.00559.x. J Thromb Haemost. 2004. PMID: 14717958 Review. No abstract available.
• [Impact of GP IIb/IIIa antagonists in interventional cardiology].

  Scheller B, Hennen B, Böhm M, Nickenig G. Scheller B, et al. Dtsch Med Wochenschr. 2003 Feb 7;128(6):281-7. doi: 10.1055/s-2003-37078. Dtsch Med Wochenschr. 2003. PMID: 12571800 Review. German. No abstract available.